Protalix BioTherapeutics is projected to report Q3 2026 revenue of $12.4 million and an EPS loss of $0.02, with its current $2.54 share price sitting significantly below the $11.50 analyst consensus target.

Investors are primarily focused on the commercial traction of Elfabrio (pegunigalsidase alfa) and the timing of inventory orders from its global partner, Chiesi.

Analysts anticipate a significant year-over-year revenue decline due to the inherently 'lumpy' nature of these partner shipments, which can vary widely quarter-to-quarter. However, management has recently reaffirmed its full-year 2026 revenue guidance of $78 million to $83 million, indicating that achieving the current Q3 target would keep the company on track for its annual objectives.